首页 > 市场调查报告书 > 製药

生物标记

市场调查报告书

商品编码

1961744

全球PARP抑制剂生物标记市场规模、份额、趋势和成长分析报告（2026-2034年）

Global PARP Inhibitor Biomarkers Market Size, Share, Trends & Growth Analysis Report 2026-2034

出版日期: 2026年02月05日 | 出版商:

Value Market Research | 英文 137 Pages | 商品交期: 最快1-2个工作天内

价格

简介目录

PARP抑制剂生物标记市场预计将从2025年的11.1亿美元成长到2034年的24.3亿美元，2026年至2034年的复合年增长率为9.11%。

受癌症发病率上升和标靶治疗需求增加的推动，PARP抑制剂生物标记市场正经历显着增长。 PARP抑制剂是一类在治疗具有特定基因突变的癌症（尤其是乳癌和卵巢癌）方面展现出良好前景的药物。随着我们对癌症生物学认识的不断深入，识别和检验能够预测PARP抑制剂疗效的生物标记对于个人化医疗至关重要。随着研究人员和临床医生不断优化治疗策略并改善患者预后，预计市场将持续扩张。

此外，生物标誌物发现技术的进步正在推动PARP抑制剂生物标记市场的创新。次世代定序技术、液态生物检体技术和生物资讯学工具的开发，提高了识别和检验与PARP抑制剂疗效相关的生物标记的能力。这些创新不仅提高了生物标记检测的准确性，也加速了伴随诊断的开发，从而指导治疗决策。随着对新型生物标记及其临床应用的持续研究，在癌症治疗准确性不断提高的预期推动下，该市场预计将进一步扩张。

此外，对个人化医疗和以患者为中心的治疗方式的日益重视正在改变PARP抑制剂生物标记的未来前景。随着医疗服务提供者越来越重视考虑个别患者特征的客製化治疗方案，对可靠生物标记以指南治疗决策的需求预计将会增加。这一趋势在临床试验和药物研发领域尤其重要，因为生物标记主导的策略可以提高新治疗方法的效率和成功率。随着PARP抑制剂生物标记市场的不断发展，技术进步、对个人化医疗的关注以及对有效癌症治疗的需求将共同作用，在塑造其未来发展轨迹方面发挥关键作用。

区域分析
北美市场分析、洞察与预测
- 我们
- 加拿大
- 墨西哥
欧洲市场分析、洞察与预测
- 英国
- 法国
- 德国
- 义大利
- 俄罗斯
- 其他欧洲国家
亚太市场分析、洞察与预测
- 印度
- 日本
- 韩国
- 澳洲
- 东南亚
- 其他亚太国家
拉丁美洲市场分析、洞察与预测
- 巴西
- 阿根廷
- 秘鲁
- 智利
- 其他拉丁美洲国家
中东和非洲市场分析、洞察与预测
- 沙乌地阿拉伯
- UAE
- 以色列
- 南非
- 其他中东和非洲国家

第八章竞争情势

最新趋势
公司分类
供应链和销售管道合作伙伴（根据现有资讯）
市场占有率和市场定位分析（基于现有资讯）
供应商情况（基于现有资讯）
策略规划

第九章：公司简介

主要公司的市占率分析
公司简介
- Myriad Genetics Inc
- Ambry Genetics
- Thermo Fisher Scientific Inc
- Illumina Inc
- Centogene NV
- Amoy Diagnostics Co. Ltd
- Invitae Corporation
- NeoGenomics Laboratories
- QIAGEN
- Agilent Technologies Inc

简介目录

Product Code: VMR112114327

The PARP Inhibitor Biomarkers Market size is expected to reach USD 2.43 Billion in 2034 from USD 1.11 Billion (2025) growing at a CAGR of 9.11% during 2026-2034.

The PARP inhibitor biomarkers market is experiencing significant growth, driven by the increasing prevalence of cancer and the rising demand for targeted therapies. PARP inhibitors are a class of drugs that have shown promise in treating cancers with specific genetic mutations, particularly in breast and ovarian cancers. As the understanding of cancer biology advances, the identification and validation of biomarkers that predict response to PARP inhibitors are becoming critical for personalized medicine. This market is expected to expand as researchers and clinicians seek to optimize treatment strategies and improve patient outcomes.

Moreover, advancements in biomarker discovery technologies are propelling innovation within the PARP inhibitor biomarkers market. The development of next-generation sequencing, liquid biopsy techniques, and bioinformatics tools is enhancing the ability to identify and validate biomarkers associated with PARP inhibitor efficacy. These innovations not only improve the accuracy of biomarker testing but also facilitate the development of companion diagnostics that can guide treatment decisions. As research continues to explore new biomarkers and their clinical applications, the market is likely to expand further, driven by the promise of improved precision in cancer therapy.

Additionally, the growing emphasis on personalized medicine and patient-centric approaches is shaping the PARP inhibitor biomarkers landscape. As healthcare providers increasingly prioritize tailored treatment plans that consider individual patient characteristics, the demand for reliable biomarkers that can inform treatment decisions is likely to increase. This trend is particularly relevant in the context of clinical trials and drug development, where biomarker-driven strategies can enhance the efficiency and success rates of new therapies. As the PARP inhibitor biomarkers market continues to evolve, the combination of technological advancements, a focus on personalized medicine, and the need for effective cancer treatments will play a crucial role in shaping its future trajectory.

Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:

Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.

Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.

Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.

Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.

Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.

Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.

Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.

MARKET SEGMENTATION

By Product

Kits
Assays

By Services

BRCA 1 & 2 Testing
HRD Testing
HRR Testing
Others

By Application

Breast Cancer
Ovarian Cancer
Others

COMPANIES PROFILED

Myriad Genetics Inc, Ambry Genetics, Thermo Fisher Scientific Inc, Illumina Inc, Centogene NV, Amoy Diagnostics Co Ltd, Invitae Corporation, NeoGenomics Laboratories, QIAGEN, Agilent Technologies Inc

We can customise the report as per your requriements

Chapter 1. PREFACE

1.1. Market Segmentation & Scope
1.2. Market Definition
1.3. Information Procurement
- 1.3.1 Information Analysis
- 1.3.2 Market Formulation & Data Visualization
- 1.3.3 Data Validation & Publishing
1.4. Research Scope and Assumptions
- 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

2.1. Market Snapshot
2.2. Segmental Outlook
2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

3.1. Market Lineage Outlook
3.2. Penetration & Growth Prospect Mapping
3.3. Value Chain Analysis
3.4. Regulatory Framework
- 3.4.1 Standards & Compliance
- 3.4.2 Regulatory Impact Analysis
3.5. Market Dynamics
- 3.5.1 Market Drivers
- 3.5.2 Market Restraints
- 3.5.3 Market Opportunities
- 3.5.4 Market Challenges
3.6. Porter's Five Forces Analysis
3.7. PESTLE Analysis

Chapter 4. GLOBAL PARP INHIBITOR BIOMARKERS MARKET: BY PRODUCT 2022-2034 (USD MN)

4.1. Market Analysis, Insights and Forecast Product
4.2. Kits Estimates and Forecasts By Regions 2022-2034 (USD MN)
4.3. Assays Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL PARP INHIBITOR BIOMARKERS MARKET: BY SERVICES 2022-2034 (USD MN)

5.1. Market Analysis, Insights and Forecast Services
5.2. BRCA 1 & 2 Testing Estimates and Forecasts By Regions 2022-2034 (USD MN)
5.3. HRD Testing Estimates and Forecasts By Regions 2022-2034 (USD MN)
5.4. HRR Testing Estimates and Forecasts By Regions 2022-2034 (USD MN)
5.5. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL PARP INHIBITOR BIOMARKERS MARKET: BY APPLICATION 2022-2034 (USD MN)

6.1. Market Analysis, Insights and Forecast Application
6.2. Breast Cancer Estimates and Forecasts By Regions 2022-2034 (USD MN)
6.3. Ovarian Cancer Estimates and Forecasts By Regions 2022-2034 (USD MN)
6.4. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 7. GLOBAL PARP INHIBITOR BIOMARKERS MARKET: BY REGION 2022-2034(USD MN)

7.1. Regional Outlook
7.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
- 7.2.1 By Product
- 7.2.2 By Services
- 7.2.3 By Application
- 7.2.4 United States
- 7.2.5 Canada
- 7.2.6 Mexico
7.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
- 7.3.1 By Product
- 7.3.2 By Services
- 7.3.3 By Application
- 7.3.4 United Kingdom
- 7.3.5 France
- 7.3.6 Germany
- 7.3.7 Italy
- 7.3.8 Russia
- 7.3.9 Rest Of Europe
7.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
- 7.4.1 By Product
- 7.4.2 By Services
- 7.4.3 By Application
- 7.4.4 India
- 7.4.5 Japan
- 7.4.6 South Korea
- 7.4.7 Australia
- 7.4.8 South East Asia
- 7.4.9 Rest Of Asia Pacific
7.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
- 7.5.1 By Product
- 7.5.2 By Services
- 7.5.3 By Application
- 7.5.4 Brazil
- 7.5.5 Argentina
- 7.5.6 Peru
- 7.5.7 Chile
- 7.5.8 South East Asia
- 7.5.9 Rest of Latin America
7.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
- 7.6.1 By Product
- 7.6.2 By Services
- 7.6.3 By Application
- 7.6.4 Saudi Arabia
- 7.6.5 UAE
- 7.6.6 Israel
- 7.6.7 South Africa
- 7.6.8 Rest of the Middle East And Africa

Chapter 8. COMPETITIVE LANDSCAPE

8.1. Recent Developments
8.2. Company Categorization
8.3. Supply Chain & Channel Partners (based on availability)
8.4. Market Share & Positioning Analysis (based on availability)
8.5. Vendor Landscape (based on availability)
8.6. Strategy Mapping

Chapter 9. COMPANY PROFILES OF GLOBAL PARP INHIBITOR BIOMARKERS INDUSTRY

9.1. Top Companies Market Share Analysis
9.2. Company Profiles
- 9.2.1 Myriad Genetics Inc
- 9.2.2 Ambry Genetics
- 9.2.3 Thermo Fisher Scientific Inc
- 9.2.4 Illumina Inc
- 9.2.5 Centogene N.V
- 9.2.6 Amoy Diagnostics Co. Ltd
- 9.2.7 Invitae Corporation
- 9.2.8 NeoGenomics Laboratories
- 9.2.9 QIAGEN
- 9.2.10 Agilent Technologies Inc

02-2729-4219

+886-2-2729-4219

License/价格

全球PARP抑制剂生物标记市场规模、份额、趋势和成长分析报告（2026-2034年）

Global PARP Inhibitor Biomarkers Market Size, Share, Trends & Growth Analysis Report 2026-2034